(Q34749759)

4 August 2017

1 reference

title

Treatment of drug-resistant pneumococcal pneumonia (English)

1 reference

4 August 2017

0 references

1

Javier Garau

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Lancet Infectious Diseases

4 August 2017

published in

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

404-415

1 reference

Impact of antibiotic resistance on chemotherapy for pneumococcal infections.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Measuring the comparative efficacy of antibacterial agents for acute otitis media: The “Pollyanna phenomenon”

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Antimicrobial Resistance in Streptococcus pneumoniae: An Overview

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Penicillin-resistant pneumococci and community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Macrolide resistance among invasive Streptococcus pneumoniae isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pneumococcal macrolide resistance-not a myth

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pneumococcal meningitis during therapy of otitis media with clarithromycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Breakthrough sepsis in macrolide-resistant pneumococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Emergence of macrolide resistance during treatment of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Primary targets of fluoroquinolones in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Antipneumococcal activities of gemifloxacin compared to those of nine other agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Ciprofloxacin in acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Pneumococcal meningitis during intravenous ciprofloxacin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Inappropriate use of oral ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

1 reference

7 January 2021

Fluoroquinolone resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Levofloxacin-resistant pneumococcus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Will pneumococci put quinolones in their place?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Assessing the quality of the Alexander Project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Treatment of pneumococcal pneumonia: the case for penicillin G.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

In-vitro killing activity of combinations of beta-lactam agents with aminoglycosides against penicillin-resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Efficacy of beta-lactam antibiotics combined with gentamicin against penicillin-resistant pneumococcal pneumonia in CBA/J mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900316-X

7 January 2021

10.1016/S1473-3099(02)00316-X

Identifiers

DOI

1 reference

4 August 2017

1 reference